Avotermin: A novel antiscarring agent

International Journal of Lower Extremity Wounds

Volumn 7, Issue 3, 2008, Pages 160-168

  Durani, Piyush ^a,c   Occleston, Nick ^c   O'Kane, Sharon ^c   Ferguson, Mark W J ^b,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Renovo   (United Kingdom)

Author keywords

Avotermin; Scars; Skin; TGF 3; Transforming growth factor 3

Indexed keywords

AVOTERMIN; ISOPROTEIN; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA3; TRANSFORMING GROWTH FACTOR BETA3;

ADULT; CLINICAL TRIAL; DRUG EFFICACY; FETUS; HEALTH CARE NEED; HUMAN; HUMAN TISSUE; MOLECULAR MECHANICS; PRIORITY JOURNAL; REVIEW; SCAR; STRUCTURE ACTIVITY RELATION;

BIOLOGICAL PRODUCTS; CICATRIX, HYPERTROPHIC; HUMANS; SKIN; TRANSFORMING GROWTH FACTOR BETA3; WOUND HEALING;

EID: 49749086125     PISSN: 15347346     EISSN: 15526941     Source Type: Journal    
DOI: 10.1177/1534734608322983     Document Type: Review

References (71)

1. Ferguson MW, O'Kane S. Scar-free healing: from embryonic mechanisms to adult therapeutic intervention. Philos Trans R Soc Lond B Biol Sci. 2004 ; 359: 839-850.
2. Ferguson MW, Whitby DJ, Shah M., Armstrong J., Siebert JW, Longaker MT Scar formation: the spectral nature of fetal and adult wound repair. Plast Reconstr Surg. 1996 ; 97: 854-860.
3. Robert R., Meyer W., Bishop S., Rosenberg L., Murphy L., Blakeney P. Disfiguring burn scars and adolescent self-esteem. Burns. 1999 ; 25: 581-585.
4. Lawrence JW, Fauerbach JA, Heinberg L., Doctor M. Visible vs hidden scars and their relation to body esteem. J Burn Care Rehabil. 2004 ; 25: 25-32.
5. Bayat A., McGrouther DA Clinical management of skin scarring. Skinmed. 2005 ; 4: 165-173.
6. Newell R. Psychological difficulties amongst plastic surgery ex-patients following surgery to the face: a survey. Br J Plast Surg. 2000 ; 53: 386-392.
7. Layton AM Optimal management of acne to prevent scarring and psychological sequelae. Am J Clin Dermatol. 2001 ; 2: 135-141.
8. Valente SM Visual disfigurement and depression. Plast Surg Nurs. 2004 ; 24: 140-146.
9. Rumsey N., Clarke A., White P. Exploring the psychosocial concerns of outpatients with disfiguring conditions. J Wound Care. 2003 ; 12: 247-252.
10. McGrouther DA Facial disfigurement. BMJ. 1997 ; 314: 991.
11. Abdullah A., Blakeney P., Hunt R., et al. Visible scars and self-esteem in pediatric patients with burns. J Burn Care Rehabil. 1994 ; 15: 164-168.
12. Bayat A., McGrouther DA, Ferguson MW Skin scarring. BMJ. 2003 ; 326: 88-92.
13. Singer AJ, Mach C., Thode HC Jr, Hemachandra S., Shofer FS, Hollander JE Patient priorities with traumatic lacerations. Am J Emerg Med. 2000 ; 18: 683-686.
14. Li-Tsang CW, Lau JC, Chan CC Prevalence of hypertrophic scar formation and its characteristics among the Chinese population. Burns. 2005 ; 31: 610-616.
15. Crossland DS, Jackson SP, Lyall R., et al. Patient attitudes to sternotomy and thoracotomy scars. Thorac Cardiovasc Surg. 2005 ; 53: 93-95.
16. Bock O., Schmid-Ott G., Malewski P., Mrowietz U. Quality of life of patients with keloid and hypertrophic scarring. Arch Dermatol Res. 2006 ; 297: 433-438.
17. Lowe T., Paoloni R. Sutured wounds: factors associated with patient-rated cosmetic scores. Emerg Med Australas. 2006 ; 18: 259-267.
18. Levine E., Degutis L., Pruzinsky T., Shin J., Persing JA Quality of life and facial trauma: psychological and body image effects. Ann Plast Surg. 2005 ; 54: 502-510.
19. Dixon AJ, Dixon MP, Dixon JB Prospective study of long-term patient perceptions of their skin cancer surgery. J Am Acad Dermatol. 2007 ; 57: 445-453.
20. Batra RS Surgical techniques for scar revision. Skin Therapy Lett. 2005 ; 10: 4-7.
21. Meier K., Nanney LB Emerging new drugs for scar reduction. Expert Opin Emerg Drugs. 2006 ; 11: 39-47.
22. Franz MG, Steed DL, Robson MC Optimizing healing of the acute wound by minimizing complications. Curr Probl Surg. 2007 ; 44: 691-763.
23. Bond J., Duncan JA, Sattar A., et al. The maturation of the human scar: an observational study. Plast Reconstruct Surg. 2008 ; 121: 1650-1658.
24. Brockes JP, Kumar A. Appendage regeneration in adult vertebrates and implications for regenerative medicine. Science. 2005 ; 310: 1919-1923.
25. Levesque M., Gatien S., Finnson K., et al. Transforming growth factor: beta signaling is essential for limb regeneration in axolotls. PLoS ONE. 2007 ; 2: e1227.
26. McCallion RL, Ferguson MWJ. Fetal wound healing and the development of antiscarring therapies for adult wound healing. In: Clark RAF, ed. The Molecular and Cellular Biology of Wound Repair. 2 nd ed. New York: Plenum Press ; 1996: 561-600.
27. Shah M., Foreman DM, Ferguson MW Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta. Lancet. 1992 ; 339: 213-214.
28. Shah M., Foreman DM, Ferguson MWJ. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci. 1995 ; 108: 985-1002.
29. Shah M., Foreman DM, Ferguson MW Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents. J Cell Sci. 1994 ; 107: 1137-1157.
30. Denhez F., Lafyatis R., Kondaiah P., Roberts AB, Sporn MB Cloning by polymerase chain reaction of a new mouse TGF-beta, mTGF-beta 3. Growth Factors. 1990 ; 3: 139-146.
31. Bassing CH, Yingling JM, Howe DJ, et al. A transforming growth factor beta type I receptor that signals to activate gene expression. Science. 1994 ; 263: 87-89.
32. Franzén P., ten Dijke P., Ichijo H., et al. Cloning of a TGFβ type I receptor that forms a heteromeric complex with the TGF-β type II receptor. Cell. 1993 ; 75: 681-692.
33. Lin HY, Wang X-F., Ng-Eaton E., Weinberg RA, Lodish HF Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase. Cell. 1992 ; 68: 775-785.
34. Lopez-Casillas F., Cheifetz S., Doody J., Andres JL, Lane WS, Massague J. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-β receptor system. Cell. 1991 ; 67: 785-795.
35. Tomoda T., Kudoh T., Noma T., Nakazawa A., Muramatsu M., Arai K. Molecular cloning of a mouse counterpart for human TGF-beta type I receptor. Biochem Biophys Res Commun. 1994 ; 198: 1054-1062.
36. Lawler S., Candia AF, Ebner R., et al. The murine type II TGF-beta receptor has a coincident embryonic expression and binding preference for TGF-beta 1. Development. 1994 ; 120: 165-175.
37. He WW, Gustafson ML, Hirobe S., Donahoe PK Developmental expression of four novel serine/threonine kinase receptors homologous to the activin/transforming growth factor-beta type II receptor family. Dev Dyn. 1993 ; 196: 133-142.
38. Kulkarni AB, Huh CG, Becker D., et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A. 1993 ; 90: 770-774.
39. Shull MM, Ormsby I., Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 1992 ; 359: 693-699.
40. Sanford LP, Ormsby I., Gittenberger-de Groot AC, et al. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development. 1997 ; 124: 2659-2670.
41. Proetzel G., Pawlowski SA, Wiles MV, et al. Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet. 1995 ; 11: 409-414.
42. Graycar JL, Miller DA, Arrick BA, Lyons RM, Moses HL, Derynck R. Human transforming growth factor-beta 3: recombinant expression, purification, and biological activities in comparison with transforming growth factors-beta 1 and -beta 2. Mol Endocrinol. 1989 ; 3: 1977-1986.
43. Jennings JC, Mohan S., Linkhart TA, Widstrom R., Baylink DJ Comparison of the biological actions of TGF beta-1 and TGF beta-2: differential activity in endothelial cells. J Cell Physiol. 1988 ; 137: 167-172.
44. Roberts AB, Kondaiah P., Rosa F., et al. Mesoderm induction in Xenopus laevis distinguishes between the various TGF-beta isoforms. Growth Factors. 1990 ; 3: 277-286.
45. Merwin JR, Newman W., Beall LD, Tucker A., Madri J. Vascular cells respond differentially to transforming growth factors beta 1 and beta 2 in vitro. Am J Pathol. 1991 ; 138: 37-51.
46. Schmid P., Cox D., Bilbe G., et al. TGF-beta s and TGFbeta type II receptor in human epidermis: differential expression in acute and chronic skin wounds. J Pathol. 1993 ; 171: 191-197.
47. Levine JH, Moses HL, Gold LI, Nanney LB Spatial and temporal patterns of immunoreactive transforming growth factor beta 1, beta 2, and beta 3 during excisional wound repair. Am J Pathol. 1993 ; 143: 368-380.
48. Smith EA, LeRoy EC A possible role for transforming growth factor-beta in systemic sclerosis. J Invest Dermatol. 1990 ; 95 (6 suppl). 125S - 127S.
49. Nikol S., Isner JM, Pickering JG, Kearney M., Leclerc G., Weir L. Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. J Clin Invest. 1992 ; 90: 1582-1592.
50. Cromack DT, Sporn MB, Roberts AB, Merino MJ, Dart LL, Norton JA Transforming growth factor beta levels in rat wound chambers. J Surg Res. 1987 ; 42: 622-628.
51. Wahl SM, Wong H., McCartney-Francis N. Role of growth factors in inflammation and repair. J Cell Biochem. 1989 ; 40: 193-199.
52. Yang EY, Moses HL Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol. 1990 ; 111: 731-741.
53. Koch RM, Roche NS, Parks WT, Ashcroft GS, Letterio JJ, Roberts AB Incisional wound healing in transforming growth factor-beta1 null mice. Wound Repair Regen. 2000 ; 8: 179-191.
54. Chan T., Ghahary A., Demare J., et al. Development, characterization, and wound healing of the keratin 14 promoted transforming growth factor-beta1 transgenic mouse. Wound Repair Regen. 2002 ; 10: 177-187.
55. Mustoe TA, Pierce GF, Thomason A., Gramates P., Sporn MB, Deuel TF Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta. Science. 1987 ; 237: 1333-1336.
56. Border WA, Noble NA Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994 ; 331: 1286-1292.
57. Okuda S., Languino LR, Ruoslahti E., Border WA Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J Clin Invest. 1990 ; 86: 453-462.
58. Raghow R. Role of transforming growth factor-beta in repair and fibrosis. Chest. 1991 ; 99 (3 suppl). 61S - 65S.
59. Broekelmann TJ, Limper AH, Colby TV, McDonald JA Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci U S A. 1991 ; 88: 6642-6646.
60. Connor TB Jr, Roberts AB, Sporn MB, et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest. 1989 ; 83: 1661-1666.
61. Logan A., Frautschy SA, Gonzalez AM, Sporn MB, Baird A. Enhanced expression of transforming growth factor beta 1 in the rat brain after a localized cerebral injury. Brain Res. 1992 ; 587: 216-225.
62. Czaja MJ, Weiner FR, Flanders KC, et al. In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis. J Cell Biol. 1989 ; 108: 2477-2482.
63. Ghosh J., Baguneid M., Khwaja N., et al. Reduction of myointimal hyperplasia after arterial anastomosis by local injection of transforming growth factor beta3. J Vasc Surg. 2006 ; 43: 142-149.
64. Murphy MO, Ghosh J., Halka AT, et al. In vivo attenuation of myointimal hyperplasia using transforming growth factor-beta3 in an interposition graft model. J Endovasc Ther. 2006 ; 13: 389-399.
65. O'Kane S., Ferguson MWJ. Transforming growth factor betas and wound healing. Int J Biochem Cell Biol. 1997 ; 29: 63-78.
66. Chen W., Fu X., Ge S., et al. Ontogeny of expression of transforming growth factor-beta and its receptors and their possible relationship with scarless healing in human fetal skin. Wound Repair Regen. 2005 ; 13: 68-75.
67. Occleston NL, Laverty HG, O'Kane S., Ferguson MWJ. Prevention and reduction of scarring in the skin by transforming growth factor beta 3 (TGFβ3): from laboratory discovery to clinical pharmaceutical. J Biomater Sci Polym Ed. 2008 ; 19: 1047-1063.
68. Bandyopadhyay B., Fan J., Guan S., et al. A "traffic control" role for TGFβ3: orchestrating dermal and epidermal cell motility during wound healing. J Cell Biol. 2006 ; 172: 1093-1105.
69. Tyrone JW, Marcus JR, Bonomo SR, Mogford JE, Xia Y., Mustoe TA Transforming growth factor beta3 promotes fascial wound healing in a new animal model. Arch Surg. 2000 ; 135: 1154-1159.
70. Cox DA Transforming growth factor-beta 3. Cell Biol Int. 1995 ; 19: 357-371.
71. Wu L., Siddiqui A., Morris DE, Cox DA, Roth SI, Mustoe TA Transforming growth factor beta 3 (TGF beta 3) accelerates wound healing without alteration of scar prominence. Histologic and competitive reverse-transcription-polymerase chain reaction studies. Arch Surg. 1997 ; 132: 753-760.